Enliven Therapeutics (NASDAQ:ELVN) CEO Samuel Kintz Sells 3,700 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 3,700 shares of the stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $20.06, for a total value of $74,222.00. Following the transaction, the chief executive officer owned 915,392 shares of the company’s stock, valued at $18,362,763.52. This represents a 0.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, September 23rd, Samuel Kintz sold 2,800 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.03, for a total value of $56,084.00.
• On Friday, September 19th, Samuel Kintz sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.25, for a total value of $20,250.00.
• On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $19.09, for a total value of $95,450.00.
• On Tuesday, August 19th, Samuel Kintz sold 590 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $11,800.00.
• On Monday, August 18th, Samuel Kintz sold 10,393 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.02, for a total value of $208,067.86.
• On Thursday, July 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total value of $281,500.00.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $19.92 on Friday. The company has a market capitalization of $1.18 billion, a P/E ratio of -9.96 and a beta of 0.85. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03. The stock has a 50 day moving average price of $19.66 and a 200-day moving average price of $19.60.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. As a group, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ELVN. GAMMA Investing LLC increased its stake in Enliven Therapeutics by 3,058.1% in the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after purchasing an additional 2,630 shares during the period. Quantbot Technologies LP purchased a new stake in Enliven Therapeutics in the first quarter worth $60,000. BNP Paribas Financial Markets increased its stake in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the period. Tower Research Capital LLC TRC increased its stake in Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after purchasing an additional 3,490 shares during the period. Finally, KLP Kapitalforvaltning AS increased its stake in Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after purchasing an additional 2,500 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. HC Wainwright raised their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, July 2nd. The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research report on Monday, June 16th. They issued a “buy” rating and a $37.00 price target for the company. Finally, Robert W. Baird raised their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, June 16th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.